MULTIFACTOR ACTION OF ANTINEOPLASTIC CHEMOTHERAPY CAPICITABINE

MULTIFACTOR ACTION OF ANTINEOPLASTIC CHEMOTHERAPY CAPECITABINE

Abstract

Introduction: The drug capecitabine, trade name Xeloda®, is used against breast cancer, colorectal prostate, and others. Its metabolite disrupts DNA synthesis by preventing the neoplastic cell from multiplying. This leads to the blockade of DNA synthesis also in healthy cells. Objective: Analysis of muscle glucose, hematological profile and electrocardiographic changes of rats treated with the drug Xeloda®. METHODS: Wistar rats aged of 3 to 4 months and weighing 180 to 200 grams of ANILAB®, without food restriction, with a constant temperature of 23 ± 2ºC and normal cycle of day and night with 12 hours, the drug was administered at a dose of 359mg / kg, dissolved in 40mM citrate buffer containing 5% arabic gum as transport. Results: Differences between the control group and the rats treated with capecitabine showed a big difference of lower values for tissue glucose, together with hematological profiles and increased values for the electrocardiogram.